Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth -
EBITDA / Sales -
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the company’s current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book -
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
ADAPTIMMUNE THERAPEUTICS PL..-33.02%561
GILEAD SCIENCES, INC.20.25%87 579
BIONTECH SE283.45%75 497
WUXI APPTEC CO., LTD.38.94%70 844
REGENERON PHARMACEUTICALS21.38%60 387
VERTEX PHARMACEUTICALS-15.22%51 872
GENMAB A/S13.80%29 283
BEIGENE, LTD.20.82%28 945
ARGENX SE4.83%15 501
HUALAN BIOLOGICAL ENGINEERI..-12.90%10 396
NEUROCRINE BIOSCIENCES, INC..-3.06%8 785
MIRATI THERAPEUTICS, INC.-27.22%8 223
FATE THERAPEUTICS, INC.-5.38%8 091
ACCELERON PHARMA INC.-0.74%7 708
ARROWHEAD PHARMACEUTICALS, ..-10.96%7 111
GW PHARMACEUTICALS PLC89.72%6 907
-
More Results